Is MDxHealth SA (MDXH) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 35.8% / 30% | 27.9% / 30% | 8.7% / 30% | 1.2% / 5% | ✗ NOT HALAL |
| DJIM | 35.8% / 33% | 27.9% / 33% | 8.7% / 33% | 1.2% / 5% | ✗ NOT HALAL |
| MSCI | 38.2% / 33% | 29.7% / 33% | 9.2% / 33% | 1.2% / 5% | ✗ NOT HALAL |
| S&P | 35.8% / 33% | 27.9% / 33% | 8.7% / 33% | 1.2% / 5% | ✗ NOT HALAL |
| FTSE | 38.2% / 33% | 29.7% / 33% | 9.2% / 50% | 1.2% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 64.5% | |
| Operating Margin | -17.8% | |
| Net Margin | -31.1% | |
| Return on Equity (ROE) | -2440.4% | |
| Return on Assets (ROA) | -5.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$19M |
| Free Cash Flow | -$21M |
| Total Debt | $60M |
| Current Ratio | 1.1 |
| Total Assets | $157M |
Price & Trading
| Last Close | $2.70 |
| 50-Day MA | $3.44 |
| 200-Day MA | $3.40 |
| Avg Volume | 121K |
| Beta | -561273.8 |
|
52-Week Range
$1.36
| |
About MDxHealth SA (MDXH)
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It also offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration with the University of Oxford: the initiation of Genomic Prostate Score (GPS) testing in the landmark UK ProtecT trial (Prostate Testing for Cancer and Treatment). The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is MDxHealth SA (MDXH) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), MDxHealth SA is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is MDxHealth SA's debt ratio?
MDxHealth SA's debt ratio is 35.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 38.2%.
What are MDxHealth SA's key financial metrics?
MDxHealth SA has a market capitalization of $125M. The company maintains a gross margin of 64.5% and a net margin of -31.1%. Return on equity stands at -2440.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.